JP2020502047A5 - - Google Patents

Download PDF

Info

Publication number
JP2020502047A5
JP2020502047A5 JP2019523589A JP2019523589A JP2020502047A5 JP 2020502047 A5 JP2020502047 A5 JP 2020502047A5 JP 2019523589 A JP2019523589 A JP 2019523589A JP 2019523589 A JP2019523589 A JP 2019523589A JP 2020502047 A5 JP2020502047 A5 JP 2020502047A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
solvate
compound according
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019523589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502047A (ja
JP6987859B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/061867 external-priority patent/WO2018093946A1/en
Publication of JP2020502047A publication Critical patent/JP2020502047A/ja
Publication of JP2020502047A5 publication Critical patent/JP2020502047A5/ja
Application granted granted Critical
Publication of JP6987859B2 publication Critical patent/JP6987859B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019523589A 2016-11-16 2017-11-15 Magl阻害剤 Expired - Fee Related JP6987859B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423095P 2016-11-16 2016-11-16
US62/423,095 2016-11-16
PCT/US2017/061867 WO2018093946A1 (en) 2016-11-16 2017-11-15 Magl inhibitors

Publications (3)

Publication Number Publication Date
JP2020502047A JP2020502047A (ja) 2020-01-23
JP2020502047A5 true JP2020502047A5 (enExample) 2020-12-17
JP6987859B2 JP6987859B2 (ja) 2022-01-05

Family

ID=62107273

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019523589A Expired - Fee Related JP6987859B2 (ja) 2016-11-16 2017-11-15 Magl阻害剤

Country Status (27)

Country Link
US (1) US9981930B1 (enExample)
EP (1) EP3541822B1 (enExample)
JP (1) JP6987859B2 (enExample)
KR (1) KR20190077087A (enExample)
CN (1) CN110248947B (enExample)
AR (1) AR110088A1 (enExample)
AU (1) AU2017361250A1 (enExample)
BR (1) BR112019009991A2 (enExample)
CA (1) CA3043612A1 (enExample)
CL (1) CL2019001335A1 (enExample)
CO (1) CO2019005038A2 (enExample)
CR (1) CR20190243A (enExample)
DO (1) DOP2019000121A (enExample)
EA (1) EA201991074A1 (enExample)
EC (1) ECSP19035377A (enExample)
ES (1) ES2908632T3 (enExample)
IL (1) IL266550A (enExample)
JO (1) JOP20190105A1 (enExample)
MA (1) MA46860A (enExample)
MX (1) MX2019005771A (enExample)
NI (1) NI201900050A (enExample)
PE (1) PE20191146A1 (enExample)
PH (1) PH12019501102A1 (enExample)
RU (1) RU2019116514A (enExample)
TN (1) TN2019000150A1 (enExample)
TW (1) TW201831458A (enExample)
WO (1) WO2018093946A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX350788B (es) 2012-01-06 2017-09-13 Abide Therapeutics Inc Compuestos de carbamato y preparación y uso de los mismos.
US10450302B2 (en) 2015-05-11 2019-10-22 Lundbeck La Jolla Research Center, Inc. Methods of treating inflammation or neuropathic pain
CN109996790B (zh) 2016-09-19 2023-05-16 H.隆德贝克有限公司 哌嗪氨基甲酸酯及其制备和使用方法
JOP20190107A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
AU2017361254B2 (en) 2016-11-16 2021-09-23 H. Lundbeck A/S. Pharmaceutical formulations
PE20191239A1 (es) 2016-11-16 2019-09-16 Abide Therapeutics Inc Formas cristalinas de un inhibidor de magl
JOP20190106A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
UA126685C2 (uk) 2017-08-29 2023-01-11 Луннбек Ла-Холья Рісьоч Сенте, Інк. Сполуки, які є модуляторами magl, і способи їх отримання і застосування
GEAP202115351A (en) * 2017-11-02 2021-12-10 Aicuris Gmbh & Co Kg Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
EP3793547A4 (en) 2018-05-15 2021-11-17 H. Lundbeck A/S MAGL INHIBITORS
AU2021259496A1 (en) 2020-04-21 2022-11-10 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
TWI904281B (zh) 2020-11-13 2025-11-11 丹麥商H 朗德貝克公司 Magl抑制劑
IL313987A (en) 2021-12-29 2024-08-01 Psy Therapeutics Inc Inhibiting monoacylglycerol lipase (magl)
IL316302A (en) 2022-05-04 2024-12-01 H Lundbeck As Crystalline form of 111333-hexafluoropro s-1-pyridazin-3-ylca azaspiro2.5octane-6- as a monoacylglycerol lipase inhibitor

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1593586A (enExample) 1967-10-17 1970-06-01
JPS6183073A (ja) 1984-10-01 1986-04-26 Oki Electric Ind Co Ltd 印字装置の用紙送り方法
WO1989011794A1 (fr) 1988-06-07 1989-12-14 Rikagaku Kenkyusho Inhibiteur de la croissance de plantes
DE69211015T2 (de) 1991-11-27 1997-01-09 Du Pont Herbizide acylierte amino-(phenyl-oder-pyridinyl-oder thienyl-)phenyl derivate
AU1384795A (en) 1993-12-22 1995-07-10 Shell Internationale Research Maatschappij B.V. Process for preparing carbamates
JP2000500448A (ja) 1995-11-15 2000-01-18 ゼネカ リミテッド 除草性置換ピラゾール化合物
AU3440597A (en) 1996-07-02 1998-01-21 Novartis Ag N-phenylimino heterocyclic derivatives and their use as herbicides
RU2167150C2 (ru) 1998-03-25 2001-05-20 Фокин Александр Васильевич Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью
WO2001025188A1 (en) 1999-10-04 2001-04-12 University Of Medicine And Dentistry Of New Jersey Novel carbamates and ureas
EP1201298A1 (en) 2000-10-24 2002-05-02 Urea Casale S.A. Carbamate condensation unit
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
FR2864080B1 (fr) 2003-12-23 2006-02-03 Sanofi Synthelabo Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
WO2005063698A1 (en) 2003-12-31 2005-07-14 Council Of Scientific & Industrial Research Process for preparing carbamates
EP1716130A1 (en) 2004-02-18 2006-11-02 AstraZeneca AB Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
CA2561564A1 (en) * 2004-04-07 2005-10-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
EP1831218A2 (en) 2004-12-23 2007-09-12 F.Hoffmann-La Roche Ag Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
EP1836179B1 (en) 2004-12-30 2015-05-06 Janssen Pharmaceutica NV Piperidine- and piperazine-1-carboxylic acid amide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions
JP2009523729A (ja) 2006-01-13 2009-06-25 ピーティーシー セラピューティクス,インコーポレーテッド C型肝炎の治療方法
EP1987037A2 (en) 2006-02-23 2008-11-05 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
EP2114941B1 (en) 2006-12-22 2015-03-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
CN101711154A (zh) 2007-02-26 2010-05-19 科森生物科学公司 氨基甲酸酯化合物
JP2008239616A (ja) * 2007-02-28 2008-10-09 Iyaku Bunshi Sekkei Kenkyusho:Kk Hdl上昇剤
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
US20110118286A1 (en) 2008-07-16 2011-05-19 Santhosh Francis Neelamkavil Bicyclic heterocycle derivatives and their use as gpcr modulators
US8772318B2 (en) 2008-11-14 2014-07-08 The Scripps Research Institute Methods and compositions related to targeting monoacylglycerol lipase
CA2755806A1 (en) 2009-03-23 2010-09-30 Msd K.K. Novel aminopyridine derivatives having aurora a selective inhibitory action
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
RU2570662C9 (ru) 2009-11-03 2016-07-20 Байер Матириальсайенс Аг Фторуретаны в качестве добавки в фотополимерной композиции
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
LT2800743T (lt) 2012-01-06 2018-06-25 Agios Pharmaceuticals, Inc. Terapiškai aktyvūs junginiai ir jų panaudojimo būdai
MX350788B (es) * 2012-01-06 2017-09-13 Abide Therapeutics Inc Compuestos de carbamato y preparación y uso de los mismos.
US9567302B2 (en) 2012-03-19 2017-02-14 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
MX2015017961A (es) * 2013-07-03 2016-10-14 Abide Therapeutics Inc Compuestos orgánicos pirrolo-pirrol carbamato y relacionados, composiciones farmacéuticas y usos médicos de los mismos.
WO2016149401A2 (en) 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
US10450302B2 (en) * 2015-05-11 2019-10-22 Lundbeck La Jolla Research Center, Inc. Methods of treating inflammation or neuropathic pain
US10463753B2 (en) * 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
WO2017197192A1 (en) * 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
JOP20190107A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190267A1 (ar) * 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl

Similar Documents

Publication Publication Date Title
JP2024050527A5 (enExample)
JP2024514837A5 (enExample)
JP2014511891A5 (enExample)
JP2020532547A5 (enExample)
JP2016531126A5 (enExample)
JP2019535723A5 (enExample)
JP2019518766A5 (enExample)
JP2010540525A5 (enExample)
JP2021523200A5 (enExample)
JP2018518537A5 (enExample)
JP2016512531A5 (enExample)
JP2019522055A5 (enExample)
JP2015508092A5 (enExample)
JP2017504642A5 (enExample)
JP2018135343A5 (enExample)
RU2016134751A (ru) Соединения
JP2014507455A5 (enExample)
JP2019516739A5 (enExample)
JP2020532545A5 (enExample)
JP2017506666A5 (enExample)
RU2017145930A (ru) МОДУЛЯТОРЫ ROR ГАММА (RORγ)
JP2016528273A5 (enExample)
JP2013542267A5 (enExample)
JP2022513449A5 (enExample)
JP2017520540A5 (enExample)